At a glance
ClinicalIndex Comparison RecordEarly Ph 1Completed· 92 enrolled
Drug / intervention
enteric-coated aspirin +1 moredrug
Likely dose
enteric-coated aspirin 81mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of Aspirin Resistance at a Molecular Level in Aspirin-Treated Patients With Coronary Artery Disease
In Brief
A Early Phase 1 clinical trial evaluating enteric-coated aspirin and Chewable aspirin for Coronary Artery Disease. Completed, enrolled 92 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate possible mechanisms of aspirin resistance at a molecular level in aspirin-treated patients with coronary artery disease. We hypothesize that certain patient characteristics associate with aspirin resistance. In addition, we will compare the effects of enteric-coated aspirin and chewable aspirin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)
Timeline
Early Ph 1CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2006
First PostedSep 2008
Primary CompletionAug 2011
Study CompletionMar 2014
TodayJul 2026
First PostedSep 17, 2008
Enrollment StartJun 1, 2006
Primary CompletionAug 1, 2011
Study CompletionMar 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 17.8 years ago
Interventions
enteric-coated aspirindrug
enteric-coated aspirin 81mg daily for 2 weeks
Chewable aspirindrug
chewable aspirin 81mg daily for 2 weeks